Why ANVISA Medical Device Approvals Fail in Brazil & How to Fix Them

1. Incorrect Device Classification

Incorrect risk classification remains the leading catalyst for extended regulatory delays and application suspensions in Brazil. Manufacturers frequently extrapolate their US FDA Class II or EU MDR Class IIa classification directly into Brazil, overlooking ANVISA’s specific classification rules codified under RDC No. 751/2022.

Common Classification Pitfalls:

• Assuming FDA Class II automatically equals ANVISA Class II without checking RDC 751/2022 Rule 1 to 22.
• Overlooking Brazil’s heightened scrutiny on active implantable devices, software algorithms (SaMD), and aesthetic medical devices.
• Misclassifying a device as a low-risk Notification (Notificação – Class I/II) when ANVISA mandates a formal Registration (Registro – Class III/IV).

Regulatory Impact:

When ANVISA discovers an under-classified device, the review protocol is suspended immediately. The applicant is forced to submit a brand-new Registro dossier, pay additional health surveillance fees (TFVS), and reset the official review queue.

The Fix: Classify your medical device strictly through the lens of ANVISA RDC 751/2022. Verify intended use, contact duration, invasiveness, and energy delivery against Brazilian classification rules before drafting technical documentation.

2. Documentation That Is “Globally Correct” but “Locally Wrong”

ANVISA accepts international clinical and bench-testing data; however, acceptance is strictly conditional upon localized regulatory formatting. Submitting a direct literal translation of a European or American dossier almost always results in official queries.

Common Localization Errors:

• Instructions for Use (IFU / Instruções de Uso): Translating manuals using automated software without aligning terminology with Brazilian clinical terminology, official metric units, and disposal guidelines.
• Missing Mandatory Portuguese Labeling Elements: Failing to include the Brazilian Registration Holder’s (BRH) corporate details, CNPJ number, technical manager (Responsável Técnico) credentials, and ANVISA registration number placeholders.
• Ignoring Local Standards: Neglecting mandatory Brazilian technical norms, such as ABNT NBR standards or compulsory certification frameworks detailed in our guide on INMETRO Certification for Medical Devices in Brazil.

The Fix: Treat Brazilian localization as an engineering and regulatory adaptation, not a translation exercise. Every document—from the risk analysis (ISO 14971) to secondary packaging mockups—must comply with Chapter VI of RDC 751/2022.

3. Misunderstanding and Mismanaging ANVISA’s Review Queries (Exigências)

When ANVISA reviewers identify inconsistencies or missing data, they issue a formal clarification notice termed an Exigência Técnica. The legal deadline to respond is typically 30 consecutive days (extendable once for an additional 30 days upon formal request). Panicked or rushed responses frequently transform a manageable query into an outright rejection.

Common Query Response Blunders:

• Over-Answering: Providing extraneous test reports, design histories, or validation files that were never requested, which opens new avenues for regulatory questioning.
• Defensive Explanations: Debating the reviewer’s clinical interpretation rather than providing empirical data, risk assessments, or localized justifications.
• Creating File Contradictions: Introducing new test versions that contradict earlier statements in the primary technical dossier.

The Fix: Respond like a regulatory authority, not a defensive manufacturer. Structure every response point-by-point, cross-referencing specific articles of ANVISA resolutions, and provide concise, verifiable documentation.

4. Assuming FDA Clearance or CE Marking Guarantees Fast-Track Approval

Relying on foreign approvals to bypass Brazilian regulatory requirements is an expensive miscalculation. While foreign clearances prove technical viability, ANVISA operates as an independent sovereign health agency.

The Regulatory Reality:

• No Automatic Reciprocity: ANVISA does not grant automatic market authorization based solely on a 510(k) clearance letter or CE Certificate.
• Different Clinical Weight: European clinical evaluations (MEDDEV or MDR CERs) may require supplementary demographic or clinical validation if the indication doesn’t reflect Brazilian epidemiological profiles.
• B-GMP Certification Requirements: For Class III and IV devices, ANVISA mandates Brazilian Good Manufacturing Practice (B-GMP) certification under RDC 665/2022 or validation via the Medical Device Single Audit Program (MDSAP).

The Fix: Leverage your international test data as supporting technical evidence, but ensure the core dossier maps directly to ANVISA’s unique regulatory structure. If you are also targeting global compliance, coordinate your submissions with specialized US FDA 510(k), QMSR & Registration consulting.

5. Poor Pre-Submission Planning and Inadequate BRH Infrastructure

Many submission failures originate months before the dossier is submitted. Foreign manufacturers without a physical presence in Brazil must appoint an authorized Brazilian Registration Holder (BRH) to hold the registration and liaise with ANVISA.

Strategic Vulnerabilities:

• Selecting commercial distributors as the legal BRH, leaving the manufacturer vulnerable to commercial hold-ups if distributor relationships deteriorate.
• Filing an application before completing mandatory local testing (e.g., INMETRO electrical safety testing under IEC 60601).
• Neglecting establishment licensing (Autorização de Funcionamento de Empresa – AFE) verification for the local warehousing partner.

The Fix: Conduct a comprehensive pre-submission readiness review. Engage an independent third-party BRH or neutral regulatory consulting partner to maintain full commercial control of your product licenses across Brazil.